Douglas Galasko

84.5k citations

295 papers · 25.2k indexed · 13 hit papers · h-index 82

Impact in

Psychiatry and Mental health top 0.02%
- Dementia and Cognitive Impairment Research
Neurology top 0.05%
- Parkinson's Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological disorders and treatments
- Neurological Disease Mechanisms and Treatments

Papers in

Psychiatry and Mental health 168
- Dementia and Cognitive Impairment Research 162
Physiology 152
- Alzheimer's disease research and treatments 148

Co-authors: David P. Salmon Lawrence A. Hansen Elaine R. Peskind Mark W. Bondi Jeffrey L. Cummings Leon J. Thal Ronald G. Thomas Eliezer Masliah
Journals: Alzheimer s & Dementia (44 papers)Neurology (28 papers)Journal of Alzheimer s Disease (24 papers)Alzheimer Disease & Associated Disorders (13 papers)Alzheimer s Research & Therapy (9 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Douglas Galasko

292 papers receiving 24.7k citations

Hit Papers

13 papers align trajectories log scale

Brain-derived tau: a novel blood-based biomarker for Alzheimer’s disease-type neurodegeneration 2022 · 134 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Brain
2022 Acta Neuropathologica
2021 The Lancet Neurology
2018 Acta Neuropathologica Communications
2014 Journal of Alzheimer s Disease
2014 Acta Neuropathologica
2010 Brain
2009 Alzheimer Disease & Associated Disorders
2007 The Lancet Neurology
2006 Alzheimer Disease & Associated Disorders
2005 New England Journal of Medicine
1995 Annals of Neurology
1990 Neurology

Peers

Countries citing papers authored by Douglas Galasko

Since Specialization

Citations

This map shows the geographic impact of Douglas Galasko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Galasko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Galasko more than expected).

Fields of papers citing papers by Douglas Galasko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Galasko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Galasko. The network helps show where Douglas Galasko may publish in the future.

Co-authors

The 25 scholars most cited alongside Douglas Galasko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Douglas Galasko Line = papers co-authored together Douglas Galasko links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Toward a biological definition of neuronal and glial synucleinopathies Nature Medicine ·Claudio Soto, Brit Mollenhauer, Oskar Hansson, Un Jung Kang, Roy N. Alcalay, David G. Standaert, Claudia Trenkwalder, Kenneth Marek, Douglas Galasko, Kathleen L. Poston	2025	5
2	Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies Alzheimer s & Dementia ·Renaud La Joie, Jeffrey L. Cummings, Jeffrey L. Dage, Douglas Galasko, Miloš D. Ikonomović, Thomas K. Karikari, Susan Landau, Jorge J. Llibre‐Guerra, Catherine J. Mummery, Rik Ossenkoppele, Julie C. Price, Shannon L. Risacher, Ruben Smith, Christopher H. van Dyck, Marı́a C. Carrillo	2025	2
3	Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies Alzheimer s & Dementia ·Jennifer G. Goldman, Bradley F. Boeve, Douglas Galasko, John‐Paul Taylor, James E. Galvin, James B. Leverenz, ‪Frederic Blanc‬, Glenda M. Halliday, Т И Савельева, Afina W. Lemstra, Iracema Leroi, Simon J.G. Lewis, Irene Litvan, Stephen Turner, John T. O’Brien, Sonja W. Scholz, Dag Aarsland, Manabu Ikeda, Ian G. McKeith, Angela E. Taylor	2025	1
4	The science does not yet support regulatory approval of amyloid‐targeting therapies for Alzheimer's disease based solely on biomarker evidence Alzheimer s & Dementia ·Vincent Planche, Suzanne E. Schindler, David S. Knopman, Giovanni B. Frisoni, Douglas Galasko, Joshua D. Grill, Lon S. Schneider, Jason Karlawish, Nicolas Villain	2025	4
5	Low testosterone levels relate to poorer cognitive function in women in an APOE-ε4-dependant manner Biology of Sex Differences ·Alexander Antonov, Sarah J. Banks, Matthew S. Panizzon, Douglas Galasko, Erin E. Sundermann, (unknown)	2024	4
6	SCRN1: A cerebrospinal fluid biomarker correlating with tau in Alzheimer's disease Alzheimer s & Dementia ·Cicero Alvarez, Mathias Sauer, Gunnar Brinkmalm, Sinem AĞCA, Radu Constantinescu, Bárbara Fernandes Gomes, Bruno Becker, Bengt Nellgård, Scott Wolfson, Douglas Galasko, Henrik Zetterberg, Kaj Blennow, Johan Gobom	2023	7
7	Limitations of the human iPSC-derived neuron model for early-onset Alzheimer’s disease Molecular Brain ·Ayush Chandra, Kenneth W. Henry, Hedwig Schultz, Koushik Muralidharan, Andrew B. Caldwell, Srinivasan Ramachandran, Lawrence S.B. Goldstein, William C. Mobley, Douglas Galasko, Shankar Subramaniam	2023	3
8	Alzheimer’s Disease Pathology in Middle Aged and Older People with HIV: Comparisons with Non-HIV Controls on a Healthy Aging and Alzheimer’s Disease Trajectory and Relationships with Cognitive Function Viruses ·Erin E. Sundermann, Laura M. Campbell, WANG Libin, Mark W. Bondi, Ben Gouaux, David P. Salmon, Douglas Galasko, Virawudh Soontornniyomkij, Ronald J. Ellis, David J. Moore	2023	4
9	Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression Journal of Parkinson s Disease ·Michael C. Brumm, Andrew Siderowf, Tanya Simuni, C. Dauccia, Seung Ho Choi, Chelsea Caspell‐Garcia, Lana M. Chahine, Brit Mollenhauer, Tatiana Foroud, Douglas Galasko, Kalpana Merchant, Vanessa Arnedo, Samantha J. Hutten, Ahmed Samir Abdul, Kathleen L. Poston, Caroline M. Tanner, Daniel Weintraub, Karl Kieburtz, Kenneth Marek, Christopher S. Coffey, (unknown)	2023	25
10	Stable Isotope Labelling Kinetics: Models and methods to evaluate APP production rates with Posiphen treatment in the DISCOVER clinical trial Alzheimer s & Dementia ·Donald L. Elbert, Douglas Galasko, Martin R. Farlow, Wiyana Pertiwi, Judy Pa, Brendan P. Lucey, Lawrence S. Honig, Abhay Moghekar, Randall J. Bateman, Jeremiah D. Momper, Robert A. Rissman, Archana B. Balasubramanian, Maria L. Maccecchini, Howard Feldman, (unknown)	2023	1
11	α‐Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α‐Synuclein in the Context of Co‐Pathology and Non‐LBD Diagnoses Annals of Neurology ·Robert Otsyina, David G. Coughlin, Barbara H. Brumbach, Denis S. Smirnov, Luis Concha‐Marambio, Carly M. Farris, Yihua Ma, L. Chen, Edward N. Wilson, Jeffrey Kaye, Annie Hiniker, Randy Woltjer, Douglas Galasko, Joseph F. Quinn	2022	55
12	TDP‐43 Pathology Exacerbates Cognitive Decline in Primary Age‐Related Tauopathy Annals of Neurology ·Denis S. Smirnov, David P. Salmon, Douglas Galasko, Steven D. Edland, Donald Pizzo, Z. Tumsavas, Annie Hiniker	2022	17
13	Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease Alzheimer s & Dementia ·Andrew B. Caldwell, 闫姿颖, Can Zhang, Gary P. Schroth, Douglas Galasko, Kevin D. Rynearson, Rudolph E. Tanzi, Shauna H. Yuan, Steven L. Wagner, Shankar Subramaniam	2022	12
14	Digital Histological Study of Neocortical Grey and White Matter Tau Burden Across Tauopathies Journal of Neuropathology & Experimental Neurology ·David G. Coughlin, Annie Hiniker, Claire Peterson, L. Chen, Jo Walgrave, Lucia Giannini, Donald Pizzo, Daniel Weintraub, Andrew Siderowf, Irene Litvan, Robert A. Rissman, Douglas Galasko, Lawrence A. Hansen, John Q. Trojanowski, Edward B. Lee, Murray Grossman, David J. Irwin	2022	7
15	CD4 ⁺ T cells contribute to neurodegeneration in Lewy body dementia Science ·David Gate, Joakim Lundblad, Olivia Leventhal, Marian Shahid, W. Kozanecki, Andrew C. Yang, A. Pozo Porta, Michael S. Unger, Tobias Fehlmann, Hamilton Oh, Divya Channappa, Victor W. Henderson, Andreas Keller, Ludwig Aigner, Douglas Galasko, Mark M. Davis, Kathleen L. Poston, Tony Wyss‐Coray	2021	131
16	Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy American Journal Of Pathology ·Yu Wang, Aneeka M. Hancock, Joshua M. Bradner, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghină, Karen L. Edwards, Katherine W. Snapinn, David S. Goldstein, Min Shi, Jing Zhang	2011	96
17	Distinct cognitive profiles and rates of decline on the Mattis Dementia Rating Scale in autopsy-confirmed frontotemporal dementia and Alzheimer's disease Journal of the International Neuropsychological Society ·Katya Rascovsky, David P. Salmon, Lawrence A. Hansen, Douglas Galasko	2008	37
18	Safety and Acceptability of the Research Lumbar Puncture Alzheimer Disease & Associated Disorders ·Elaine R. Peskind, Robert G. Riekse, Joseph F. Quinn, Jeffrey Kaye, Christopher M. Clark, Martin R. Farlow, Charles DeCarli, Charles Chabal, Darcy Vavrek, Murray A. Raskind, Douglas Galasko	2005	149
19	A Multicenter Evaluation of New Treatment Efficacy Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders ·Steven H. Ferris, Joan Mackell, Richard C. Mohs, Lon S. Schneider, Douglas Galasko, Peter J. Whitehouse, Frederick A. Schmitt, Mary Sano, Ronald G. Thomas, Christopher Ernesto, Michael Grundman, Kimberly Schafer, Leon J. Thal	1997	37
20	Multicenter Evaluation of New Instruments for Alzheimerʼs Disease Clinical Trials Alzheimer Disease & Associated Disorders ·Joan Mackell, Steven H. Ferris, Richard C. Mohs, Lon S. Schneider, Douglas Galasko, Peter J. Whitehouse, Frederick A. Schmitt, Mary Sano, Leon J. Thal	1997	13

About Douglas Galasko

Douglas Galasko is a scholar working on Psychiatry and Mental health, Physiology, Neurology, Geriatrics and Gerontology and Neurology, having authored 295 papers that have together received 25.2k indexed citations. Recurring topics across this work include Dementia and Cognitive Impairment Research (162 papers), Alzheimer's disease research and treatments (148 papers), Parkinson's Disease Mechanisms and Treatments (63 papers), Cholinesterase and Neurodegenerative Diseases (20 papers), Neurological disorders and treatments (19 papers), Functional Brain Connectivity Studies (18 papers), Health Systems, Economic Evaluations, Quality of Life (14 papers) and S100 Proteins and Annexins (12 papers). The work is most often cited by research in Psychiatry and Mental health (11.5k citations), Neurology (4.2k citations), Physiology (11.9k citations), Neurology (5.5k citations) and Biological Psychiatry (586 citations). Douglas Galasko has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include David P. Salmon, Lawrence A. Hansen, Elaine R. Peskind, Mark W. Bondi, Jeffrey L. Cummings, Leon J. Thal, Ronald G. Thomas, Eliezer Masliah, L. J. Thal and Joseph F. Quinn. Their work appears in journals such as Alzheimer s & Dementia, Neurology, Journal of Alzheimer s Disease, Alzheimer Disease & Associated Disorders and Alzheimer s Research & Therapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact